Study drug for adults with bloodstream or deep Candida infection
Treatments studied
Part of Infections clinical trials.
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (at least 18, or older than your country’s consent age) and can consent (or a legal representative can).
- Your Candida infection is confirmed by a sample taken within the last 4 days, and your diagnosis fits the study’s timing window before randomization.
- Your care team can do “source control,” such as removing infected lines/catheters or devices if needed.
- Your infection is not caused by Candida krusei, and it’s not a certain type of deep Candida infection the study excludes.
- You are not expected to die within 72 hours, and you do not need dialysis (hemodialysis, peritoneal dialysis, or hemofiltration).
- You have not had certain recent treatments or study drugs, and your liver health is not severely impaired.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a shorter course of the antifungal drug caspofungin (7 days instead of the usual 14) is just as effective for people with uncomplicated candidemia, a bloodstream infection caused by Candida yeast. If you've already had 7 days of caspofungin and your blood is clear of Candida, you might be able to stop treatment sooner.
This trial compares a shorter course of antifungal medicine to a longer one for people who have candidemia (a yeast infection in the blood). It looks at whether treating for a shorter time is just as safe and effective, which could mean fewer side effects and a quicker recovery.
This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.
This trial compares shorter vs longer treatment for children with an uncomplicated yeast (Candida) bloodstream infection once blood cultures are clear. It may help reduce medicine exposure while keeping the infection under control.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
This program provides access to an experimental antifungal drug called fosmanogepix for people with serious or life-threatening fungal infections that haven't responded to other treatments. It's for those who have no other options left.
Hear when a new Candidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.